Pronto Diagnostics is a leading provider of molecular diagnostic products with extensive knowledge, experience, and R&D capabilities in SNP-based analysis of genetic variations.
The company specializes in developing diagnostic kits for clinical diagnosis of genetic disease, carrier screening, prenatal testing, disease predisposition, and differential diagnosis and is active in the rapidly growing field of pharmacogenetics and personalized medicine.
PRONTO® has developed and introduced to the market over 30 test kits which provide rapid and accurate assays for detecting polymorphisms in DNA sequences associated with genetic diseases and predisposition to disease. The kits are suitable for both small and large-scale clinical genetic analysis.
Our products are based on the patented PRONTO® technology. The technology forms the basis for one of the first commercial SNP assays for clinical diagnostics that utilizes a single-nucleotide primer extension ELISA assay.
The PRONTO® product line has received CE certification and meets the highest international quality production standards including ISO 9001:2000, EN 46001, and ISO 13485.
Pronto Diagnostics provides highly professional technical support. Its product specialists are dedicated to supporting the company's customers worldwide. Its proprietary technologies and applications allow the company to meet growing market needs, while setting the standard for clinical genetic analysis products.
The company has developed molecular pharmacogenetic assays (PGx) to address toxicity and metabolism of specific drugs, such as 5-FU, warfarin (Coumadin) and morphine as well as assays to test the genetic variability in several PGx related genes such as Cytochrome P450 2D6.
ProntoLabTM , the molecular services division of Pronto Diagnostics, provides clinical molecular diagnostics services as well as research services which include:
Pronto Diagnostics has been granted exclusive distribution rights in Israel to high quality products and technologies from:
Since 2004, Pronto Diagnostics has been retained to perform all operating and commercial activities for Aferrix Ltd., a diagnostic start-up which is an innovator in the analysis of plasma iron levels. Aferrix’s activities include providing iron-overload testing services to both pharmaceutical companies (such as Novartis) and to researchers.
